Belgium· BE-AMP-SAM281601-00

Eloxatin 5 mg/ml

A oxaliplatin product containing oxaliplatin, registered in Belgium by Sanofi Belgium. The same ATC class is registered in 17 of our 19 countries.

ATC L01XA03

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedEloxatin 5 mg/mlATCL01XA03REGISTER NO.BE-AMP-SAM281601-00PACKS LISTED2CHECKEDSeptember 26, 2026

Where it is registered

Oxaliplatin is registered in 17 of 19 countries.

Countries holding a registration under ATC L01XA03 (oxaliplatin), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 9 of them publish a price we can compare per daily dose

Oxaliplatin · ATC L01XA03

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of oxaliplatin costs, country by country.

Normalised to the WHO defined daily dose (11 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Oxaliplatin · price per daily dose (11 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$24.21
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Oxaliplatin
Manufacturer
Sanofi Belgium
Country
Belgium (BE)
ATC code
L01XA03
ATC class
Oxaliplatin
Defined daily dose
11 mg, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    0784272
  • be_apb
    2325868

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

740 interactions on record for oxaliplatin.

Graded by severity as the source publishes them — 101 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Oxaliplatin · interactions on record

740 records

  • 101 severe
  • 453 moderate
  • 1 minor
  • 185 info

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • QuinidineC01BA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Oxaliplatin in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All oxaliplatin products

Authorised across Europe · EMA

The same active substance is authorised in 29 EEA countries. Names it is sold under:

  • Austria · Ebeoxal, Oxaliplatin Accord
  • Bulgaria · Оксалиплатин Акорд, Оксалиплатин Булгермед
  • Cyprus · Oxaliplatin
  • Czechia · Oxaliplatin Accord, Oxaliplatin Agmed
  • Germany · Eloxatin, Medoxa
  • Denmark · Oxaliplatin Accord, Oxaliplatin Actavis
  • Estonia · Oxaliplatin Accord, Oxaliplatin Kabi
  • Spain · Oxaliplatino Accord, Oxaliplatino Aurovit
  • Finland · Oxaliplatin Accord
  • France · Dacplat, Eloxatine
  • United Kingdom (Northern Ireland) · Oxaliplatin Accord Healthcare, Oxaliplatin Amarox
  • Greece · Elatofen, Oxaliplatin Deltapharma
  • Croatia · Oksaliplatin Kalceks, Oxaliplatin Kabi
  • Hungary · Oxaliplatin Accord, Oxaliplatin Kabi
  • Ireland · Oxaliplatin Accord Healthcare Ireland, Oxaliplatin Fresenius Kabi Deutschland
  • Iceland · Oxaliplatin Actrevo, Oxaliplatin Teva
  • Italy · Oxaliplatino Accord, Oxaliplatino Aurobindo
  • Lithuania · Oxaliplatin Accord, Oxaliplatin Kabi
  • Luxembourg · Eloxatin, Oxaliplatine Fresenius Kabi
  • Latvia · Oxaliplatin Accord, Oxaliplatin Kabi
  • Malta · Oxaviatin
  • Netherlands · Oxaliplatin Hikma, Oxaliplatine Accord
  • Norway · Oksaliplatin Sun, Oxaliplatin Fresenius Kabi
  • Poland · Oxaliplatin Ebewe, Oxaliplatin Eugia
  • Portugal · Oxaliplatina Accord, Oxaliplatina Aurovitas
  • Romania · Oxaliplatin Accord, Oxaliplatin Aqvida Gmbh
  • Sweden · Oxaliplatin Accord, Oxaliplatin Eugia
  • Slovenia · Oksaliplatin Kabi, Oksaliplatin Sandoz
  • Slovakia · Oxaliplatin Agmed, Oxaliplatin Kabi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/640208e1-e50c-47c8-b404-0d47fa4b473f
GET /v1/drugs/640208e1-e50c-47c8-b404-0d47fa4b473f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentrate for solution for infusion",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Eloxatin 5 mg/ml",
  "name_fr": "Eloxatin 5 mg/ml",
  "name_nl": "Eloxatin 5 mg/ml",
  "amp_code": "SAM281601-00",
  "strengths": [
    "5.0000"
  ],
  "pack_count": 1,
  "substances": [
    "Oxaliplatin"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Oxaliplatin",
  "authorisation_numbers": [
    "BE281601"
  ]
}

See everything about oxaliplatin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.